Lenoss closed a $6M growth bridge in March on the back of a record Q4 for OsteoPearl®, their biological allograft for vertebral compression fractures. Procedure volume nearly doubled year over year. The patent estate now stands at 23 granted, with new protections in the U.S. and Europe.
